tbuckley/cabot-search huggingface dataset:
Pharmacogenomics-Based Drug Response Prediction Model for Acute Myeloid Leukemia with Normal Karyotype
Authors: Dong Hwan (Dennis) Kim, Boram Han, Kyusang Lee, TaeJin Ahn, Dae-soon Son, Insuk Sohn, Sin-Ho Jung, Kyunghee Park, Jun Ho Jang, Kihyun Kim, Hyeoung Joon Kim, Sang Kyun Sohn, Joon Ho Moon, Jhingook Kim, Nam Huh, Chul Won Jung
Journal: Blood (2010)
Abstract B13: High-content imaging to quantitate colorectal cancer associated fibroblast heterogeneity
Authors: Colleen M. Garvey, Oscar Chen, Roy Lau, Shannon M. Mumenthaler
Journal: Cancer Research (2017)

Abstract Cancer-associated fibroblasts (CAFs) are an important component of the tumor microenvironment known to influence various aspects of tumor progression, including response to therapy. However, this stromal cell subtype is extremely heterogeneous, both between and within individual tumors. Targeting of the CAF population has not been successful in the clinical setting, which could be due in part to the myriad of functions of different CAF subpopulations. In order to elucidate the overall implications of CAF heterogeneity, we gathered quantitative phenotypic data using a novel high-content imaging platform. Specifically, we calculated several morphological parameter values and estimated birth and death rates of individual populations of CAFs isolated from colorectal cancer patients. We also performed co-culture experiments with tumor cells and characterized the influence of different CAF populations on tumor evolutionary dynamics (i.e. birth and death rates) in response to drug treatment. Further, these features were correlated to molecular analyses (i.e. -smooth muscle actin and fibroblasts activated protein expression) and patient outcome (i.e. sites of metastasis). We observed high levels of heterogeneity in cell area and cell roundness as well as altered rates of growth in response to perturbations in oxygen levels. This quantitative method for investigating multiple cellular phenotypes provides novel insight into patient-level heterogeneity and its possible implications on response to drug. Citation Format: Colleen M. Garvey, Oscar Chen, Roy Lau, Shannon M. Mumenthaler. High-content imaging to quantitate colorectal cancer associated fibroblast heterogeneity. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B13.
Patient‐reported outcome measures and qualitative research in dermatology: the quest for authenticity
Authors: C.J. Apfelbacher, P.A. Nelson
Journal: British Journal of Dermatology (2017)

'Although dermatologists think we have insight into the patient's perspective, in reality, we are not that good at understanding it.'1 Fitting then that a key tenet of the BJD's 2015 position statement2 was a commitment to better understanding patients' perspectives through high‐quality qualitative dermatology research and the creation of a dedicated qualitative section. Three editorials in a series (see Fig. 1) have, to date, focused on different aspects of qualitative research in dermatology: the added value it offers; how 'quality' might be judged; and the wide range of approaches and methods available.3,4,5 In this latest editorial, we turn in detail to the development and validation of patient‐reported outcome (PRO) measures, a 'mixed‐methods' process in which qualitative research plays a key role. A PRO is defined as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else.6 The measurement of PROs has become an important component of outcomes assessment in clinical research,7 and – more recently – in routine health care.8 Examples of PROs include instruments that measure health‐related quality of life (HRQOL) such as the Dermatology Life Quality Index (DLQI),9 symptoms or treatment satisfaction. In eczema, Heinl et al.10 reviewed all randomized controlled trials conducted in patients between 2000 and 2014 and found that 93% of the 303 trials reviewed included at least one PRO.
First in Human Engraftment of Anti-HIV Lentiviral Vector Gene Modified CD34+ Peripheral Blood Progenitor Cells in the Treatment of AIDS Related Lymphoma (ARL).
Authors: Amrita Krishnan, John A. Zaia, John Rossi, David DiGiusto, Michael Kalos, Larry Couture, Joseph Alvarnas, Mingjie Li, Haitang Li, Jiing-Kuan Yee, Priscilla Yam, Shirley Li, Shu Mi, Lijing Li, David Hsu, Michelle Wardlow, Lupe Duarte, Anitha Rao, Stephen J. Forman
Journal: Blood (2008)
Double Loading of Dendritic Cell MHC Class I and MHC Class II with an AML Antigen Repertoire Enhances Primary and Secondary T-Cell Responses In Vitro.
Authors: William K. Decker, Dongxia Xing, Sufang Li, Simon N. Robinson, Hong Yang, Ting Niu, Michael W. Thomas, Harry Segall, John D. McMannis, Richard E. Champlin, Elizabeth J. Shpall
Journal: Blood (2004)
Single-molecule sequencing and chromatin conformation capture enable de novo reference assembly of the domestic goat genome
Authors: Derek M Bickhart, Benjamin D Rosen, Sergey Koren, Brian L Sayre, Alex R Hastie, Saki Chan, Joyce Lee, Ernest T Lam, Ivan Liachko, Shawn T Sullivan, Joshua N Burton, Heather J Huson, John C Nystrom, Christy M Kelley, Jana L Hutchison, Yang Zhou, Jiajie Sun, Alessandra Crisà, F Abel Ponce de León, John C Schwartz, John A Hammond, Geoffrey C Waldbieser, Steven G Schroeder, George E Liu, Maitreya J Dunham, Jay Shendure, Tad S Sonstegard, Adam M Phillippy, Curtis P Van Tassell, Timothy P L Smith
Journal: Nature Genetics (2017)
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
Authors: Lucia Masarova, Keyur P Patel, Kate J Newberry, Jorge Cortes, Gautam Borthakur, Marina Konopleva, Zeev Estrov, Hagop Kantarjian, Srdan Verstovsek
Journal: The Lancet Haematology (2017)
Allogeneic Hematopoietic Stem-Cell Transplantation In Early Phase Might Overcome the Adverse Prognosis of Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34)/DEK-NP214(CAN) Rearrangement. A Retrospective Analysis From the Acute Leukemia Working Party of EBMT
Authors: Jordi Esteve, Myriam Labopin, Gerard Socie, Per T. Ljungman, Johan Maertens, Antonius V.M.B. Schattenberg, Sebastien Maury, Jean-Pierre Jouet, Emmanuelle Polge, Vanderson Rocha, Mohamad Mohty
Journal: Blood (2010)
Genetic Instability in Remission Hematopoiesis Is Different from That in AML Blasts: A New Diagnostic Tool to Study Biology of AML.
Authors: Albrecht Reichle, Birgit Panzer, Gerlinde Goetz, Michael Raffer, Matthias Zaiss, Reinhard Andreesen, Peter Wild, Ferdinand Hofstaedter, Wolfgang Dietmaier
Journal: Blood (2004)
Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)
Authors: Max S Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Andre C. Schuh, Janet Franklin, Kun Nie, Ze Cong
Journal: Blood (2016)
Abstract A13: Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer
Authors: Leah Cook, Arturo Araujo, Julio Pow-Sang, Mikalai Budzevich, David Basanta, Conor C. Lynch
Journal: Cancer Research (2017)

Abstract The ability to rapidly assess the efficacy of therapeutic strategies for incurable bone metastatic prostate cancer is an important and urgent need. Pre-clinical in vivo models provide insights yet are limited in their capacity to interrogate temporal multi-cellular interactions occurring in the cancer-bone microenvironment. Computational and mathematical models that integrate and, are validated experimentally, can overcome this limitation and accelerate biological research. Here, we describe how a biologically driven discrete continuum hybrid cellular automaton (HCA) model approach can dissect the pleiotropic effects of inhibiting putative therapeutic targets such as, TGFβ. Using our HCA model, we tested five different therapeutic doses delivered in two therapeutic windows. In silico results predict that TGFβ inhibition, applied prior to tumor seeding acts by directly impacting prostate cancer cell viability but also by simultaneously restricting osteoclast formation and unexpectedly, promoting osteoblast differentiation. This effect was dependent on the prostate cancer cell expression of TGFβ receptors. In silico predictions were validated with two independent in vivo models of bone metastatic prostate cancer (PAIII and C4-2B). Using immunohistochemical information from human bone metastatic prostate cancer samples, we also demonstrate how the HCA can be used to predict the evolution of heterogeneous disease in response to applied therapies. Collectively, these data underscore the power of a combined HCA/biological approach in optimizing the efficacy of applied therapies and measuring their impact on bone metastatic prostate cancer. Citation Format: Leah Cook, Arturo Araujo, Julio Pow-Sang, Mikalai Budzevich, David Basanta, Conor C. Lynch. Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr A13.
Identification of Chromosomal Abnormalities in Healthy Bone Marrow Using 250K SNP Arrays.
Authors: Christine L. O’Keefe, Lukasz P. Gondek, Ramon Tiu, Zachary P. Nearman, Marcin Wlodarski, Yasuhito Nannya, Seishi Ogawa, Jaroslaw P. Maciejewski
Journal: Blood (2006)
Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer
Authors: Nir Peled, Laila C. Roisman, Benjamin Miron, Raphael Pfeffer, Richard B. Lanman, Maya Ilouze, Addie Dvir, Lior Soussan-Gutman, Fabrice Barlesi, Gabi Tarcic, Oded Edelheit, David Gandara, Yehiel Elkabetz
Journal: Journal of Thoracic Oncology (2017)
Icaritin efficacy and tolerability in advanced hepatocellular carcinoma: Final phase Ib result.
Authors: Ying Fan, Binghe Xu, Xiaoyan Ding, Fei Ma, Jiayu Wang, Peng Yuan, Qing Li, Pin Zhang, Kun Meng, Zhaoyi Wang, Shu Li, Jun Bao
Journal: Journal of Clinical Oncology (2014)

e15107 Background: Hepatocellular carcinoma (HCC) is a highly malignant tumor with poor prognosis and limited treatment options. ER-α36 was recently discovered in several tumors and may play important roles in tumor progression. Icaritin, a prenylflavonoid derived from Chinese herb Epimedium, is an ER-α36 modifier, which demonstrated potent anti-tumor effects in preclinical studies. Icaritin also inhibits growth of hepatic cancer stem cells through down-regulating STAT activationwhich promotes hepatic cancer stem cell growth. A phase Ib study was carried out to determine safety and potential efficacy of Icaritin, in advanced solid tumors with majority of HCCs. Methods: In this phase Ib study, patients with advanced solid tumors (18 HCCs, 3 intrahepatic cholangiocarcinoma, 2 colorectal and 2 breast cancers) were given either 600 or 800 mg icaritin twice daily (BID). The results of efficacy and toxicity in HCC patients are analyzed and reported. Biopsy samples were collected for exploratory analyses of genomic expression and cytokine such as IL-6, IL-6 receptor, HGF. Results: Out of 18 HCC patients (average age = 55 yrs old ranging 31-73), 12 received icaritin 600 mg BID and 6 received 800 mg BID. 16 patients had prior hepatic B virus infection. 13 patients were evaluable for objective response. 1 got partial response lasted 12 months and 6 had stable disease (clinical benefit rate = 53.8%). The median time to tumor progression was 168 days. Patients were allowed to receive icaritin after disease progression under physician's discretion. Patients were also followed up for overall survival data. Only grade 1 drug-related adverse events were observed which includes neutropenia, ALT elevation, hypercholesteremia, fatigue, anorexia, hypertriglyceridemia, proteinuria, myalgia, hot flash and rash. SAEs such as jaundice, gastrocintestinal bleeding were reported but determined to be non-drug related. Conclusions: Icaritin was generally well-tolerated without much safety concerns. Promising antitumor activities were observed in advanced HCC patients. Further study in advanced HCC patients is warranted. Final results including overall survival, genomic and biomarker examination will be presented. Clinical trial information: NCT01278810.
Nondiagnostic ST Elevations With Chest Pain
Authors: Margaret Wei, Daniel R. Sanchez, Ivan Rokos
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Serum Free Light Chain (SFLC) Elevation Is Associated with High β2-Microglobulin and with a Shorter Time to Treatment in Waldenström Macroglobulinemia (WM).
Authors: Raphael Itzykson, Magali Le Garff-Tavernier, Sandrine Katsahian, Marie-Claude Diemert, Laurence Guis, Sylvain Choquet, Lucile Musset, Veronique Leblond
Journal: Blood (2006)
Endothelial Cell-Derived Microparticules (EMPs) Can Induce In Vitro Maturation of Both Plasmocytoid and Myeloid Dendritic Cells.
Authors: Francine Garnache-Ottou, Fanny Angelot, Sabeha Biichle, Joel PLumas, Francoise Dignat George, Philippe Saas, Pierre Tiberghien, Estelle Seilles
Journal: Blood (2006)
A Case Control Study of Deep Venous Thrombosis in Relation to Factor V G1691A (Leiden) and A4070G (HR2 Haplotype) Polymorphisms.
Authors: Wassim Y. Almawi, Lobna Borgi-Bouaziz, Hezard Nathalie, Nguyen Philipe, Mahjoub Touhami
Journal: Blood (2006)
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year
Authors: Domenico Russo, Michele Baccarani, Giovanni Martinelli, Chiara Colombi, Michele Malagola, Cristina Skert, Simona Soverini, Ilaria Iacobucci, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Bruno Cesana, Gianantonio Rosti
Journal: Blood (2011)
The Role of Pioglitazone in the Management of Nonalcoholic Steatohepatitis
Authors: Hal F. Yee
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract P5-07-09: Stem cell-like transcriptional reprogramming in metastatic resistance
Authors: MA Pujana, F Mateo, EJ Arenas, R Gomis
Journal: Cancer Research (2017)

Abstract Whether an aggressive phenotype is promoted through adaptation or resistance to target inhibition remains poorly understood. Here, complementary studies in human tumors, xenograft models and cell lines reveal transcriptional reprogramming that supports metastasis in response to PI3K/mTOR inhibition. This feature is driven by stem cell-like transcription factors. These factors functionally cooperate to promote transcriptional up-regulation of key mTOR pathway components and of metastasis mediators. Their expression is also associated with stem cell-like and metastasis signatures in tumors, and their depletion impairs the metastatic potential of breast cancer cells.Whether an aggressive phenotype is promoted through adaptation or resistance to target inhibition remains poorly understood. Here, complementary studies in human tumors, xenograft models and cell lines reveal transcriptional reprogramming that supports metastasis in response to PI3K/mTOR inhibition. This feature is driven by stem cell-like transcription factors. These factors functionally cooperate to promote transcriptional up-regulation of key mTOR pathway components and of metastasis mediators. Their expression is also associated with stem cell-like and metastasis signatures in tumors, and their depletion impairs the metastatic potential of breast cancer cells. Citation Format: Pujana MA, Mateo F, Arenas EJ, Gomis R. Stem cell-like transcriptional reprogramming in metastatic resistance [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-07-09.
The Sickle Cell Trait and Surgical Complications
Authors: Stephen A. Atlas
Journal: JAMA (1974)

Fifty-six black patients with sickle cell trait, who underwent surgical or diagnostic procedures, were matched for medical procedure, type of anesthesia, age, and sex with black subjects with normal hemoglobin. The frequency and types of complications, and length of stay for the two groups were compared. No significant differences between the two groups were observed on the basis of any of these criteria. (<i>JAMA</i>229:1078-1080, 1974)
Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey
Authors: Jamile M. Shammo, Rachel L Mitchell, Kylene Ogborn, Ellen Salkeld, Stephanie Chisolm
Journal: Blood (2015)
Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years
Authors: Ranjana H. Advani, Hailun Li, Richard T. Hoppe, Nancy L. Bartlett, John M. Bennett, Donna S. Neuberg, Peter A Cassileth, Brad S. Kahl, Sandra J. Horning
Journal: Blood (2012)
Abstract P4-05-02: Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development
Authors: L Sheng, AG Turner, GA Tarulli, K Barratt, R Kremer, HA Morris, DF Callen, PH Anderson
Journal: Cancer Research (2017)

Abstract The biologically active form of vitamin D (1,25(OH)2D) regulates proliferation, differentiation, and apoptosis in diverse cell types. We have previously identified anti-proliferative activities of 1,25(OH)2D in human breast tissue, as well as 1,25(OH)2D target gene expression consistent with reports that elevated vitamin D levels may protect against cancer. In mouse studies, vitamin D signaling modulates normal mammary gland development, including ductal outgrowth and branching, and protects against tumorigenesis. Degradation of 1,25(OH)2D is initiated by the enzyme Cyp24a1 in target tissues, providing critical local control of 1,25(OH)2D bioactivity. In vitro, blockade of Cyp24a1 activity potentiates the anti-proliferative effects of 1,25(OH)2D. However, the extent to which endogenous Cyp24a1 activity within the mammary epithelium regulates local 1,25(OH)2D levels to modulate normal mammary gland development, with possible implications for cancer, has not been investigated. We generated a novel mouse model with conditional knockout of the Cyp24a1 gene specifically in the mammary epithelium (MMTV-Cre x Cyp24a1lox/lox). Ablation of Cyp24a1 activity in the mammary epithelium does not alter either gland or body weight at 4, 6 or 10 weeks of age. Preliminary analyses of mammary gland whole mounts indicate that virgin knockout mice form fewer terminal end buds compared to glands from wild-type littermates at 4 and 6 weeks of age (P&amp;lt;0.05). Moreover, the width of the ducts proximal to the central lymph node of knockout mice was less than that of wild-type mice at 4 and 10 weeks of age (P&amp;lt;0.05 and P&amp;lt;0.01, respectively). In addition, the number of secondary and tertiary branching points is reduced in mammary glands from knockout mice at 6 weeks of age (P&amp;lt;0.05 and P&amp;lt;0.01, respectively). In summary, our findings suggest that Cyp24a1 activity within epithelial cells plays a crucial role to modulate postnatal mammary gland development, presumably by limiting the local accumulation of 1,25(OH)2D. Citation Format: Sheng L, Turner AG, Tarulli GA, Barratt K, Kremer R, Morris HA, Callen DF, Anderson PH. Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-05-02.
Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73–5
Authors: Kenneth A. Iczkowski
Journal: European Urology (2017)